ClinicalTrials.gg
TerminatedNCT01840943Updated Dec 23, 2015Results posted

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

A Phase 3 interventional study of CAELYX and Topotecan HCl in Epithelial Ovarian Cancer, sponsored by Xian-Janssen Pharmaceutical Ltd.. Terminated at 7 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-23.

Sponsored by Xian-Janssen Pharmaceutical Ltd. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Why this study was terminated
the study was terminated due to medication supply issue from current manufacturer

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing liposomal doxorubicin in Carcinoma, Ovarian Epithelial — none open to participants now, none under way, none of them phase 3. liposomal doxorubicin · Carcinoma, Ovarian Epithelial.

Enrollment
8th of 14
32 · median 33
Started
2013
the only one that year
Phase 3
2 of 14
none open now
Registered
9th of 14
by date

Among the 14 studies testing liposomal doxorubicin in Carcinoma, Ovarian Epithelial, this one is the 8th largest by enrollment, is the only one that started in 2013, is one of 2 in phase 3, and was the 9th registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

None of the 14 studies testing liposomal doxorubicin in Carcinoma, Ovarian Epithelial is open now. The open studies under Carcinoma, Ovarian Epithelial, anywhere →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing liposomal doxorubicin in Carcinoma, Ovarian Epithelial as a file.
02

Study summary

The purpose of this study is to compare the effectiveness between CAELYX and topotecan hydrochloride (HCl) in Chinese participants with recurrent epithelial ovarian carcinoma following failure of first-line, platinum-based chemotherapy, who have received no more than one prior platinum-based regimen therapy.

Read the detailed description

This is an open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), comparative bridging study (a supplemental study which performs to provide data of effectiveness, safety, and dosage to compare two study medications in a new region). The study consists of 3 phases: screening phase (30 days before administration of study medication), treatment phase, and follow up phase (every 8 weeks for tumor assessment until disease progression or death, or until the study completion, whichever is earlier and every 3 months after disease progression for overall survival and for anti-tumor therapy for a minimum of 1 year). In the treatment phase, approximately 120 eligible participants will be categorized prospectively for platinum-sensitivity (sensitive versus refractory) and bulky disease (presence versus absence). Later on participants will be randomly assigned either to experimental arm (CAELYX: administer on Day 1 of each cycle) or control arm (topotecan HCl: administer on Day 1 to Day 5 of each cycle). Treatment will continue until disease progression occurs and may continue for at least 2 cycles after confirmed complete response (disappearance of all target lesions). On average, it is expected that participants will continue treatment for approximately 3 to 6 cycles in experimental arm (CAELYX) or 4 to 8 cycles in Control arm (topotecan HCl). Safety evaluations will include assessment of adverse events, clinical laboratory tests, electrocardiogram, echocardiogram (or multiple gated acquisition scans), vital signs, and physical examination which will be monitored throughout the study. The total duration of the study will be approximately 23 months.

03

Conditions studied

  • Epithelial Ovarian Cancer

Keywords

  • Epithelial ovarian cancer
  • Recurrent epithelial ovarian carcinoma
  • Carcinoma
  • Malignancy
  • Ovarian carcinoma
  • CAELYX
  • Topotecan hydrochloride
  • Topotecan
  • Platinum-based regimen chemotherapy
  • Chinese patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosed with epithelial ovarian carcinoma with
  • Recurrent epithelial ovarian carcinoma or disease progression following failure of , platinum-based chemotherapy with no more than one prior platinum based regimen therapy
  • Adequate laboratory values of bone marrow function, renal function, liver function, and echocardiogram tests
  • Agrees to use protocol-defined effective . A woman must agree not to donate eggs (ova, oocytes) for the purpose of assisted reproduction
  • Disease-free from prior for more than 5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or breast feeding or planning to become pregnant while enrolled in this study or within 1 year after the last dose of study medication
  • Myocardial infarct within 6 months before enrollment, class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities
  • Uncontrolled systemic infection that requires systemic anti-infective treatment
  • Prior therapy with CAELYX or topotecan HCl
  • Prior chemotherapy within 28 days of first dose of study medication (or 42 days if participant has received a nitrosourea or mitomycin)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    CAELYX

    Participants will receive CAELYX 50 mg per square meter intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing PK evaluation.

    Drug: CAELYX

  • Active comparator
    Topotecan hydrochloride (HCl)

    Participants will receive topotecan HCl 1.25 mg per square meter per day, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.

    Drug: Topotecan HCl

Interventions

  • DrugCAELYX

    CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.

  • Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Progression-free Survival Incidence at Week 24

    Progression-free survival incidence was be measured as number of participants who were progression-free and alive. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Week 24

Secondary outcomes

  1. Duration of Progression-free Survival

    It was calculated as the time, in weeks, from the day of randomization until documented disease progression or death due to any cause, whichever occurs first using a Kaplan-Meier curve for PFS.

    Time frame: 1 year after the last dose (24 weeks) administration

  2. Number of Participants With Response

    Response rate was measured as number of participants with at least a durable response: Complete response (CR) or partial response (PR). Complete response is defined as the disappearance of all target lesions. Partial response is defined as at least a 30 percentage decrease in the sum of diameters of target lesions. Stable disease defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Progression in disease is defined as at least a 20% increase in the sum of diameters of target lesions. Not evaluable participants were those who were not analyzed. The reference of the baseline sum of diameters of lesions was considered.

    Time frame: Up to Week 24

  3. Time to Response

    It is calculated as the day of randomization to the first observation of a durable response (the first of the 2 confirmatory measurements).

    Time frame: Up to Week 24

  4. Duration of Response

    It is calculated as the first observation of a durable response (the first of the 2 confirmatory measurements) to the first observation of disease progression or death due to any cause.

    Time frame: Up to 1 year of last dose (Week 24) administration

  5. Health-related Quality of Life Assessment (HQL)

    Calculation of each HQL domain scale will be performed according to the scoring guidelines for each of the HQL measures. The HQL analyses will include scales measuring physical functioning, pain, nausea, fatigue, and global quality of life. Each item is measured on a scale of 0 to 3, where 0 = no impact on quality of life and 3 = extreme impact on quality of life.

    Time frame: Day 1 of each cycle of study medication and Week 4 after last dose of study medication

  6. Number of Participants With Overall Survival

    Number of Participants With Overall survival were categorized as number of 1) Deaths, 2) Still alive, 3) Early termination from the study due to lost to follow up, 4) Early termination from the study due to withdraw of consent, 5) Other. Overall survival is defined as the time interval from randomization to death from any cause.

    Time frame: Week 4 after the last dose of the study medication and approximately up to 1 year after the disease progression or completion of the study treatment or death, whichever is earlier

  7. Maximum Plasma Concentration of CAELYX

    Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

  8. Time to Reach the Maximum Plasma Concentration of CAELYX

    Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

  9. Area Under the Plasma Concentration of CAELYX

    Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

  10. Apparent Terminal Elimination Half-life of Plasma Concentration of CAELYX

    Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

  11. Apparent Terminal Elimination Rate Constant of Plasma Concentration of CAELYX

    Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

  12. Systemic Clearance of Plasma Concentration of CAELYX

    Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

  13. Apparent Volume of Distribution of Plasma Concentration of CAELYX

    Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

  14. Number of Participants With Adverse Events

    An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grade 3 (Severe) events are symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events are Symptoms causing inability to perform basic self-care functions or Medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.

    Time frame: Up to 30 days after the last dose of study medication

07

Results

Posted Dec 23, 2015
Limitations and caveats
The study was terminated early as the total number of participants treated in this study was low and only descriptive analysis was used for efficacy and safety evaluation.

Participant flow

Participant flow — Overall Study
MilestoneCAELYXTopotecan Hydrocloride (HCl)
Started1412
Completed10
Not completed1312
Withdrew: Withdrawal by subject56
Withdrew: Physician decision42
Withdrew: Lost to follow-up44

Outcome measures

PrimaryNumber of Participants With Progression-free Survival Incidence at Week 24

Progression-free survival incidence was be measured as number of participants who were progression-free and alive. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Week 24
Reported as:
Number · participants
Number of Participants With Progression-free Survival Incidence at Week 24
participantsCAELYXTopotecan Hydrocloride (HCl)
Number of Participants With Progression-free Survival Incidence at Week 2462
SecondaryDuration of Progression-free Survival

It was calculated as the time, in weeks, from the day of randomization until documented disease progression or death due to any cause, whichever occurs first using a Kaplan-Meier curve for PFS.

Time frame:
1 year after the last dose (24 weeks) administration
Reported as:
Median · weeks
Duration of Progression-free Survival
weeksCAELYXTopotecan Hydrocloride (HCl)
Duration of Progression-free SurvivalNA (8.0 to NA)24.6 (7.9 to 25.1)
SecondaryNumber of Participants With Response

Response rate was measured as number of participants with at least a durable response: Complete response (CR) or partial response (PR). Complete response is defined as the disappearance of all target lesions. Partial response is defined as at least a 30 percentage decrease in the sum of diameters of target lesions. Stable disease defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Progression in disease is defined as at least a 20% increase in the sum of diameters of target lesions. Not evaluable participants were those who were not analyzed. The reference of the baseline sum of diameters of lesions was considered.

Time frame:
Up to Week 24
Reported as:
Number · participants
Number of Participants With Response
participantsCAELYXTopotecan Hydrocloride (HCl)
Complete Response (CR)00
Partial Response (PR)53
Stable Disease (SD)46
Progression Disease (PD)11
Not Evaluable (NE)42
SecondaryTime to Response

It is calculated as the day of randomization to the first observation of a durable response (the first of the 2 confirmatory measurements).

Time frame:
Up to Week 24
Reported as:
Median · weeks
Time to Response
weeksCAELYXTopotecan Hydrocloride (HCl)
Time to Response16.0 (8.0 to 24.1)16.0 (6.0 to 16.1)
SecondaryDuration of Response

It is calculated as the first observation of a durable response (the first of the 2 confirmatory measurements) to the first observation of disease progression or death due to any cause.

Time frame:
Up to 1 year of last dose (Week 24) administration
Reported as:
Median · weeks
Duration of Response
weeksCAELYXTopotecan Hydrocloride (HCl)
Duration of ResponseNA (8.1 to NA)9.3 (8.6 to 10.6)
SecondaryHealth-related Quality of Life Assessment (HQL)

Calculation of each HQL domain scale will be performed according to the scoring guidelines for each of the HQL measures. The HQL analyses will include scales measuring physical functioning, pain, nausea, fatigue, and global quality of life. Each item is measured on a scale of 0 to 3, where 0 = no impact on quality of life and 3 = extreme impact on quality of life.

Time frame:
Day 1 of each cycle of study medication and Week 4 after last dose of study medication

No measurements were reported for this outcome.

SecondaryNumber of Participants With Overall Survival

Number of Participants With Overall survival were categorized as number of 1) Deaths, 2) Still alive, 3) Early termination from the study due to lost to follow up, 4) Early termination from the study due to withdraw of consent, 5) Other. Overall survival is defined as the time interval from randomization to death from any cause.

Time frame:
Week 4 after the last dose of the study medication and approximately up to 1 year after the disease progression or completion of the study treatment or death, whichever is earlier
Reported as:
Number · participants
Number of Participants With Overall Survival
participantsCAELYXTopotecan Hydrocloride (HCl)
Death10
Still alive00
Early termination: due to lost to follow up44
Early termination: due to withdraw of consent56
Other42
SecondaryMaximum Plasma Concentration of CAELYX
Time frame:
0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

No measurements were reported for this outcome.

SecondaryTime to Reach the Maximum Plasma Concentration of CAELYX
Time frame:
0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

No measurements were reported for this outcome.

SecondaryArea Under the Plasma Concentration of CAELYX
Time frame:
0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

No measurements were reported for this outcome.

SecondaryApparent Terminal Elimination Half-life of Plasma Concentration of CAELYX
Time frame:
0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

No measurements were reported for this outcome.

SecondaryApparent Terminal Elimination Rate Constant of Plasma Concentration of CAELYX
Time frame:
0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

No measurements were reported for this outcome.

SecondarySystemic Clearance of Plasma Concentration of CAELYX
Time frame:
0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

No measurements were reported for this outcome.

SecondaryApparent Volume of Distribution of Plasma Concentration of CAELYX
Time frame:
0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events

An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grade 3 (Severe) events are symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events are Symptoms causing inability to perform basic self-care functions or Medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.

Time frame:
Up to 30 days after the last dose of study medication
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsCAELYXTopotecan Hydrocloride (HCl)
TEAEs1212
TESAEs11

Adverse events

Collected over Up to 30 days after the last dose of study medication. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CAELYX—1/14 (7.1%)12/14 (85.7%)
Topotecan Hydrocloride (HCl)—1/12 (8.3%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventCAELYXTopotecan Hydrocloride (HCl)
Platelet count decreasedInvestigations0/141/12
Pulmonary tuberculosisInfections and infestations1/140/12
Most frequent other events
Showing 10 of 50
Most frequent other events
EventCAELYXTopotecan Hydrocloride (HCl)
AnemiaBlood and lymphatic system disorders5/1411/12
White blood cell count decreasedInvestigations6/1410/12
Neutrophil count decreasedInvestigations6/149/12
VomitingGastrointestinal disorders5/148/12
Platelet count decreasedInvestigations0/146/12
NauseaGastrointestinal disorders6/145/12
LeukopeniaBlood and lymphatic system disorders5/142/12
NeutropeniaBlood and lymphatic system disorders5/141/12
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders5/140/12
Aspartate aminotransferase increasedInvestigations3/140/12

Baseline characteristics

The modified intent-to-treat population included (mITT) included all randomized participants.

Age, Continuous
Age, Continuous(years)CAELYXTopotecan Hydrocloride (HCl)Total
Mean56.1 ± 4.9751.6 ± 8.3254.0 ± 6.96
Sex: Female, Male
Sex: Female, Male(Participants)CAELYXTopotecan Hydrocloride (HCl)Total
Female141226
Male000
08

Study locations

7 sites
  • Beijing, China
  • Chang Sha, China
  • Guangzhou, China
  • Jinan, China
  • Nanjing, China
  • Nanning, China
  • Wuhan, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of May 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2013
First posted
Apr 26, 2013
Start
Jun 2013
Primary completionActual
May 2014
CompletionActual
Aug 2014
Results first posted
Dec 23, 2015
Last update
Dec 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01840943
Responsible party
Sponsor
First posted
Apr 26, 2013
Start date
Jun 2013
Primary completion
May 2014
Completion
Aug 2014
Results posted
Dec 23, 2015
Last update
Dec 23, 2015

Study contacts

Xian-Janssen Pharmaceutical Ltd., China Clinical Trial
study director · Xian-Janssen Pharmaceutical Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal doxorubicin

Start the discussion